PTC Therapeutics PTCT Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's business segments — net income loss?
- PTC Therapeutics (PTCT) reported business segments — net income loss of -$2.81M in Q1 2026.
- How has PTC Therapeutics's business segments — net income loss changed year-over-year?
- PTC Therapeutics's business segments — net income loss decreased by 100.3% year-over-year, from $866.56M to -$2.81M.
- What is the long-term trend for PTC Therapeutics's business segments — net income loss?
- Over 2 years (2022 to 2024), PTC Therapeutics's business segments — net income loss has grown at a -19.4% compound annual growth rate (CAGR), from -$559.02M to -$363.3M.
- What does business segments — net income loss mean?
- This represents the final bottom-line profitability of the life science segment after accounting for all revenues, operating expenses, and segment-specific allocations. It is the definitive measure of the segment's financial viability and contribution to the overall corporate bottom line.